Sponsor

Bicara Therapeutics Inc.

United States 116 Huntington Avenue Suite 703, 02116-5784, United States

About the sponsor

Bicara Therapeutics Inc. focuses on recurrent or metastatic head and neck squamous cell carcinoma, with clinical interest centered on disease control in advanced head and neck cancer settings.

Head and neck squamous cell carcinoma
Recurrent disease
Metastatic disease

The sponsor’s clinical activity is concentrated in treatment strategies for patients with advanced solid tumours arising in the head and neck region.

About Specializations

Bicara Therapeutics Inc. runs clinical trials in conditions such as Squamous cell carcinoma of head and neck, among others.

Squamous cell carcinoma of head and neck

Recruiting now

Ongoing trials

Clinical trials run by this sponsor – those enrolling participants first.

Quick filters

1 clinical trial

Squamous cell carcinoma of head and neck

Recruiting

Registered drug

Study of ficerafusp alfa and pembrolizumab as first treatment for patients with PD-L1-positive recurrent or metastatic head and neck cancer

Registered drug

Austria

Participants:18–64 years · 65+ years
Substances:Pembrolizumab
Sponsor:Bicara Therapeutics Inc.

Contact Research Centre

Are you running a clinical trial?

Increase visibility for your trials and help patients find your site through our platform.

Join now →